Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis

Ionis Pharmaceuticals reported $944 million in 2025 revenue with seven marketed RNA-targeted antisense medicines spanning SMA, ALS, ATTRv-PN, HAE, and FCS. Two independent U.S. launches are underway—TRYNGOLZA (FDA-approved December 2024 for familial chylomicronemia syndrome) and DAWNZERA (FDA-approved August 2025 for hereditary angioedema)—while SPINRAZA, commercialized by partner Biogen worldwide, is the global market leader for spinal muscular atrophy. The company held $2.7 billion in cash and short-term investments at December 31, 2025.

Ionis earns revenue through product sales from independently commercialized U.S. medicines, royalties and milestones from Biogen (for SPINRAZA and QALSODY commercialized worldwide) and AstraZeneca (WAINUA co-commercialized in the U.S., with AstraZeneca holding exclusive rest-of-world rights), and distribution arrangements for TEGSEDI and WAYLIVRA through Sobi in Europe and PTC Therapeutics in Latin America. The majority of U.S. target patients rely on Medicare, Medicaid, managed care, and private insurance for coverage; pricing is subject to the IRA's Medicare Drug Price Negotiation Program, which selects up to 20 single-source drugs per year and could materially reduce per-unit reimbursement for selected products. Third-party manufacturers supply drug substance and drug product for TRYNGOLZA, DAWNZERA, and WAINUA, with many suppliers located outside the United States, exposing the company to tariff-related cost increases. The wholly owned late-stage pipeline includes obudanersen in Phase 3 for Angelman syndrome (advanced Q2 2025), zilganersen with NDA submitted in January 2026 for Alexander disease, and olezarsen under priority FDA review for severe hypertriglyceridemia with a PDUFA date of June 30, 2026.